A PHASE 2B, MULTICENTER, DOUBLE-BLIND, ACTIVE-CONTROLLED, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DIFFERENT COMBINATION REGIMENS INCLUDING JNJ-73763989 AND/OR JNJ-5616379 FOR THE TREATMENT OF CHRONIC HEPTATIS B VIRUS INFECITON
- Registry ID
- 73763989HPB2001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- JANSSEN INC
- Start date
- 2019-11-14
- Completion date
- 2022-07-27
- Last update
- 2019-07-12
Conditions
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ALG-000184 COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN UNTREATED HBEAG-POSITIVE AND HBEAG-NEGATIVE ADULT SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (B-SUPREME)
- A PHASE 2B, MULTI-CENTRE, RANDOMIZED, PARTIALLY PLACEBO-CONTROLLED, DOUBLE-BLIND
STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SEQUENTIAL THERAPY WITH
DAPLUSIRAN/TOMLIGISIRAN FOLLOWED BY BEPIROVIRSEN IN PARTICIPANTS WITH CHRONIC
HEPATITIS B VIRUS ON BACKGROUND NUCLEOS(T)IDE ANALOGUE THERAPY (B-UNITED)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE
EFFICACY AND SAFETY OF TREATMENT WITH BEPIROVIRSEN IN PARTICIPANTS LIVING WITH
HUMAN IMMUNODEFICIENCY VIRUS AND CHRONIC HEPATITIS B VIRUS INFECTION ON
ANTIRETROVIRAL TREATMENT
- A PHASE 2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF REGIMENS CONTAINING VIR-2218, VIR-3434, AND/OR PEG-IFN¿ IN SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION
- A PHASE 1B/2A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY EVALUATING THE SAFETY, ANTI-VIRAL ACTIVITY, AND PHARMACOKINETICS OF AB-423, A HBV CORE INHIBITOR, IN NON-CIRRHOTIC, HBV-DNA POSITIVE SUBJECTS WITH CHRONIC HBV INFECTION
- A PHASE 2, OPEN-LABEL, RANDOMIZED, TWO PART, MULTIPLE DOSE STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFICACY OF SB 9200 IN SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS
View on source registry